FDA Scolds Texas Drugmaker Over STD Product Promos

Law360, New York (January 28, 2014, 4:50 PM EST) -- Texas drugmaker Mission Pharmacal Co. distributed promotional materials for sexually transmitted disease medicine Tindamax that misled customers by overstating benefits and downplaying risks, according to a U.S. Food and Drug Administration letter released Monday.

The so-called untitled letter, which represents a gentler form of rebuke than a warning letter, focused largely on Mission's alleged failure to explicitly provide risk information in its sales sheet for Tindamax. Instead, the materials directed readers to separate full prescribing information, a two-tier form of communication that the FDA often criticizes....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.